Aplastic Anemia (ICD-11: 3A70) - Complete Coding and Diagnostic Guide

1. Introduction

Aplastic anemia represents a serious hematological condition characterized by bone marrow failure to produce adequate blood cells. This rare but potentially fatal disease results in pancytopenia - simultaneous reduction of red blood cells, white blood cells, and platelets - compromising vital functions of the organism. Adequate understanding of this condition is fundamental for healthcare professionals, especially in the context of precise clinical coding.

Aplastic anemia can be acquired or constitutional, affecting individuals of all age groups, although it presents peaks of incidence in young adults and elderly individuals. Its multifactorial etiology includes exposure to toxic agents, medications, viral infections, autoimmune diseases, and genetic causes, with the origin remaining idiopathic in many cases. The impact of this disease transcends clinical aspects, significantly affecting patients' quality of life due to complications associated with blood cell deficiency.

From an epidemiological perspective, aplastic anemia is considered a rare disease, but its clinical relevance is disproportionate to its prevalence. Complications include serious infections from neutropenia, potentially fatal bleeding from thrombocytopenia, and debilitating symptoms of anemia. Early diagnosis and appropriate treatment are crucial for prognosis, making it essential that healthcare professionals recognize its manifestations.

Correct coding using the ICD-11 system is critical for multiple aspects of medical care: it enables appropriate epidemiological tracking, facilitates clinical research, ensures appropriate reimbursement of procedures, enables outcome analysis, and contributes to public health policies based on precise data. The specific code 3A70 for aplastic anemia should be applied judiciously, differentiating it from other forms of anemia that require distinct codes.

2. Correct ICD-11 Code

Code: 3A70

Description: Aplastic anemia

Parent category: Anemias or other erythrocyte disorders

Official definition: Disease caused by determinants that arise after birth, in the prenatal period or by genetically inherited factors leading to the inability of stem cells to generate new mature cells. This disease is characterized by decreased levels of red blood cells, white blood cells, and platelets. This disease may manifest with pallor, fatigue, dizziness, increased risk of infections, ecchymosis, and bleeding.

Code 3A70 represents a comprehensive category that encompasses various forms of aplastic anemia, both acquired and constitutional. The ICD-11 classification recognizes the complexity of this condition, allowing specific subcategories for different etiologies and clinical presentations. This code belongs to the chapter on diseases of the blood and hematopoietic organs, reflecting its nature as a primary bone marrow disorder.

The official definition emphasizes three fundamental aspects: the failure of hematopoiesis (production of blood cells), the resulting pancytopenia, and the spectrum of clinical manifestations. It is important to note that code 3A70 is not limited to idiopathic cases, also including forms with identifiable etiology. Clinical documentation should specify, when possible, the underlying cause, severity, and specific characteristics of the case.

3. When to Use This Code

Code 3A70 should be applied in specific clinical situations where there is diagnostic confirmation of aplastic anemia. Below, we present detailed practical scenarios:

Scenario 1: Idiopathic Acquired Aplastic Anemia An adult patient presents with progressive fatigue, gingival bleeding, and recurrent infections over the past three months. Complete blood count reveals severe pancytopenia with hemoglobin of 7 g/dL, neutrophils of 400/mm³, and platelets of 15,000/mm³. Bone marrow biopsy demonstrates marked hypocellularity (less than 25% cellularity) with replacement by adipose tissue. After extensive investigation, no specific cause is identified. This is the classic scenario for application of code 3A70.

Scenario 2: Drug-Induced Aplastic Anemia A patient undergoing treatment with chloramphenicol develops progressive pancytopenia. Discontinuation of the medication does not result in hematologic recovery after an adequate observation period. Bone marrow biopsy confirms aplasia. Even with an identifiable etiology (drug-induced), code 3A70 is appropriate and may be complemented with an external cause code when relevant for documentation.

Scenario 3: Constitutional Aplastic Anemia A child with a family history of hematologic disorders presents with pancytopenia since early childhood. Genetic investigation confirms a mutation associated with hereditary aplastic anemia. Although specific subtypes exist for some constitutional forms, code 3A70 serves as the principal code when the specific form does not have its own category.

Scenario 4: Post-Hepatitis Aplastic Anemia A patient develops severe pancytopenia two to three months after an episode of viral hepatitis. The temporal association and exclusion of other causes establish the diagnosis of post-hepatitis aplastic anemia. Code 3A70 is applicable and may be complemented with a code for the prior hepatitis when clinically relevant.

Scenario 5: Aplastic Anemia Secondary to Toxic Exposure A worker with chronic exposure to benzene or other organic solvents develops progressive pancytopenia. Occupational investigation confirms significant exposure, and bone marrow biopsy documents aplasia. Code 3A70 is used as the principal diagnosis of the hematologic condition.

Scenario 6: Relapse of Aplastic Anemia A patient previously successfully treated for aplastic anemia presents with recurrence of pancytopenia with bone marrow confirmation of new aplasia. Code 3A70 remains appropriate to document the relapse, with additional specification of recurrence status in the clinical documentation.

4. When NOT to Use This Code

Appropriate differentiation is crucial to avoid incorrect coding. Code 3A70 should NOT be used in the following situations:

Pure Red Cell Aplasia: When there is isolated suppression of the red cell series without significant involvement of leukocytes and platelets, specific codes for pure red cell aplasia are more appropriate. The distinguishing characteristic is the absence of pancytopenia - only red blood cell production is compromised.

Transient Cytopenias: Temporary reductions in blood cells secondary to acute viral infections, nutritional deficiencies, or reversible medication effects do not constitute aplastic anemia. These conditions generally resolve with treatment of the underlying cause and do not present with persistent bone marrow aplasia.

Myelodysplasia: Although it may present with cytopenias, myelodysplastic syndrome has distinct morphologic characteristics in the bone marrow, with cellular dysplasia and cellularity generally normal or increased, unlike the hypocellularity characteristic of aplastic anemia. Specific codes for myelodysplasia should be used.

Leukemias with Aleukemic Presentation: Some acute leukemias may present with peripheral pancytopenia, but the bone marrow shows infiltration by blast cells, not aplasia. Differentiation is made through bone marrow aspirate and biopsy.

Hypersplenism: Increased destruction of blood cells by an enlarged spleen may cause cytopenias, but the bone marrow remains hypercelular and reactive, in contrast to the hypocellularity of aplastic anemia.

Severe Nutritional Anemias: Severe deficiencies of vitamin B12 or folate may cause cytopenias, but present with specific morphologic characteristics (megaloblastosis) and preserved or increased bone marrow cellularity.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnostic confirmation of aplastic anemia requires systematic and careful evaluation. Initially, a complete blood count must document pancytopenia, defined by reduction of at least two of the three cell lines. Quantitative criteria include reduced hemoglobin, decreased absolute neutrophil count, and thrombocytopenia.

Reticulocyte count is essential, and should be inadequately low for the degree of anemia, reflecting insufficient bone marrow production. This finding differentiates aplastic anemia from hemolytic anemias, where reticulocytes would be elevated as a compensatory response.

Bone marrow examination is mandatory for diagnostic confirmation. Bone marrow biopsy must demonstrate significant hypocellularity, generally less than 25% of the expected cellularity for age. Replacement of hematopoietic tissue by adipose tissue is characteristic. Bone marrow aspirate frequently results in a "dry tap" due to scarcity of cells.

Cytogenetic and molecular studies are important to exclude other conditions and identify possible constitutional causes. Testing for paroxysmal nocturnal hemoglobinuria should be performed, as this condition may coexist with aplastic anemia.

Step 2: Verify Specifiers

The severity of aplastic anemia must be classified based on established criteria. The severe form is defined by bone marrow cellularity less than 25% and at least two of the following: neutrophils below 500/mm³, platelets below 20,000/mm³, or reticulocytes below 20,000/mm³. The very severe form presents with neutrophils below 200/mm³.

Disease duration must be documented, differentiating acute from chronic presentations. Temporal evolution influences therapeutic decisions and prognosis. Acute cases frequently require urgent intervention, while chronic forms may have a more indolent course.

Etiology, when identifiable, should be specified in clinical documentation. Idiopathic acquired forms, drug-induced, post-infectious, or toxic exposure forms have different implications for management and prognosis. Constitutional forms require family genetic investigation.

Step 3: Differentiate from Other Codes

Nutritional or metabolic anemias: The main difference lies in bone marrow cellularity. Anemias due to iron, vitamin B12, or folate deficiency present with hypercelular bone marrow with specific morphological characteristics (microcytosis, megaloblastosis). Response to nutritional replacement is rapid and complete, unlike aplastic anemia which does not respond to supplementation.

Hemolytic anemias: Characterized by increased destruction of erythrocytes with hypercelular bone marrow and compensatory reticulocytosis. Hemolysis markers (elevated indirect bilirubin, increased LDH, reduced haptoglobin) are present. Aplastic anemia presents with low reticulocytes and absence of hemolysis signs.

3A50 - Thalassemias: Are genetic disorders of hemoglobin synthesis with specific morphological characteristics in erythrocytes (microcytosis, hypochromia, target cells). Bone marrow is hypercelular with ineffective erythropoiesis. Family history and hemoglobin studies confirm the diagnosis. Aplastic anemia presents with pancytopenia and bone marrow hypocellularity.

Step 4: Required Documentation

Adequate documentation should include:

Mandatory Checklist:

Complete blood count with differential count and reticulocytes
Bone marrow biopsy result with cellularity percentage
Bone marrow aspirate report describing cytological characteristics
Exclusion of other causes of pancytopenia (virological studies, nutritional evaluation)
Severity classification (non-severe, severe, very severe)
History of exposures (medications, toxins, radiation)
Family history of hematological disorders
Cytogenetic studies when performed
Screening for paroxysmal nocturnal hemoglobinuria

Adequate Record: Clinical documentation should clearly describe the initial presentation, laboratory findings with specific values, bone marrow results with interpretation, diagnostic reasoning including differential diagnoses considered and excluded, severity classification, and etiology when identifiable.

6. Complete Practical Example

Clinical Case

A 28-year-old female patient, previously healthy, seeks medical care with a complaint of progressive fatigue for two months, associated with cutaneous and mucosal pallor, spontaneous ecchymoses on lower limbs, and gingival bleeding when brushing teeth. She also reports three episodes of pharyngitis in the last six weeks, treated with antibiotics. She denies regular medication use, occupational exposure to toxins, or family history of hematologic diseases.

On physical examination, she appears in fair general condition, pale (++/4+), with multiple ecchymoses in different stages of evolution on lower limbs, petechiae on upper limbs, and oropharyngeal hyperemia without exudate. Absence of lymphadenopathy or hepatosplenomegaly.

Initial Investigation: Complete blood count revealed severe pancytopenia:

Hemoglobin: 6.8 g/dL
Leukocytes: 2,100/mm³ (neutrophils: 420/mm³, lymphocytes: 1,600/mm³)
Platelets: 18,000/mm³
Reticulocytes: 0.3% (absolute count: 15,000/mm³)

Peripheral blood smear showed normocytic normochromic anemia, leukopenia with neutropenia, without immature cells or blasts. Thrombocytopenia confirmed.

Serum biochemistry, renal and hepatic function, and iron studies within normal limits. Vitamin B12 and folate normal. Viral serologies (HIV, hepatitis B and C, EBV, CMV) negative. Paroxysmal nocturnal hemoglobinuria screening by flow cytometry negative.

Bone Marrow Biopsy: Biopsy of the posterior iliac crest was performed. The material obtained showed marked hypocellularity, with cellularity estimated at 15% (expected for age: 70-80%). Nearly complete replacement of hematopoietic tissue by adipose tissue. Absence of fibrosis, neoplastic infiltration, or dysplasia. Rare megakaryocytes. Findings compatible with severe aplastic anemia.

Bone marrow aspirate demonstrated scarcity of cellular material ("dry tap"), with rare elements from all three hematopoietic lineages, without morphologic atypia.

Cytogenetic study of bone marrow revealed no chromosomal abnormalities.

Step-by-Step Coding

Criteria Analysis:

Confirmed pancytopenia: Reduction of all three cell lineages documented on complete blood count
Inadequately low reticulocytes: Indicating bone marrow productive failure
Severe bone marrow hypocellularity: Biopsy confirming less than 25% cellularity
Exclusion of other causes: Extensive investigation excluded nutritional deficiencies, infections, neoplastic infiltration, and hemolysis
Severity classification: Criteria for severe aplastic anemia met (cellularity <25% + neutrophils <500/mm³ + platelets <20,000/mm³ + reticulocytes <20,000/mm³)

Selected Code: 3A70 - Aplastic Anemia

Complete Justification:

Code 3A70 is appropriate because the case meets all diagnostic criteria for aplastic anemia: peripheral pancytopenia with bone marrow hypocellularity confirmed by biopsy, absence of alternative diagnoses after comprehensive investigation, and typical clinical manifestations (fatigue, bleeding, recurrent infections).

The clinical presentation with progressive fatigue reflects the anemia, spontaneous bleeding correlates with severe thrombocytopenia, and recurrent infections result from neutropenia. Physical examination confirmed pallor and hemorrhagic manifestations without organomegaly, a pattern typical of aplastic anemia.

Bone marrow biopsy is the diagnostic gold standard, unequivocally demonstrating severe hypocellularity with adipose replacement, excluding other causes of pancytopenia such as myelodysplasia (which would present with cellular dysplasia) or leukemia (which would show blastic infiltration).

Classification as severe aplastic anemia has important therapeutic implications, indicating the need for immunosuppressive treatment or bone marrow transplantation. This information should be documented clinically, although code 3A70 is sufficient for primary coding.

Complementary Codes:

In this specific case, there is no need for additional codes, as no specific external cause or complications requiring separate coding were identified. In situations where identifiable etiology is present (medication-related, for example), complementary codes for external cause may be appropriate for complete documentation.

7. Related Codes and Differentiation

Within the Same Category

Nutritional or Metabolic Anemias:

The main difference lies in pathophysiology and bone marrow findings. Nutritional anemias result from specific deficiencies (iron, vitamin B12, folate) with hypercellular bone marrow attempting to compensate for ineffective production. Aplastic anemia presents with hypocellular marrow due to failure of stem cells.

Use nutritional anemia codes when: there is laboratory evidence of specific deficiency, typical morphological characteristics (microcytosis in iron deficiency, megaloblastosis in B12/folate deficiency), hypercellular bone marrow, and rapid response to nutritional replacement.

Use 3A70 when: pancytopenia with hypocellular marrow, absence of nutritional deficiencies or inadequate response to replacement, and biopsy confirming aplasia.

Hemolytic Anemias:

Hemolytic anemias are characterized by increased destruction of erythrocytes with hypercellular bone marrow and compensatory reticulocytosis. Laboratory markers include elevated indirect bilirubin, increased LDH, and reduced haptoglobin.

Use hemolytic anemia codes when: reticulocytosis present, positive hemolysis markers, hypercellular bone marrow with erythroid hyperplasia, and absence of significant leukopenia/thrombocytopenia.

Use 3A70 when: inadequately low reticulocytes, absence of hemolysis signs, pancytopenia, and hypocellular marrow.

3A50 - Thalassemias:

Thalassemias are genetic disorders of hemoglobin synthesis with familial inheritance pattern. They present with disproportionate microcytosis relative to the degree of anemia, characteristic erythrocyte morphology, and hypercellular marrow.

Use 3A50 when: positive family history, marked microcytosis, abnormal hemoglobin study, typical erythrocyte morphology (target cells), and hypercellular marrow.

Use 3A70 when: absence of typical thalassemia familial pattern, normocytosis or macrocytosis, pancytopenia, and hypocellular marrow.

Differential Diagnoses

Myelodysplastic Syndrome: May present with cytopenias, but marrow shows morphological dysplasia, variable cellularity (usually normal or increased), and frequent cytogenetic abnormalities. More common in elderly patients.

Aleukemic Acute Leukemia: May present with peripheral pancytopenia, but marrow shows blastic infiltration, not aplasia. Immunophenotyping identifies abnormal blastic population.

Lymphoma with Bone Marrow Involvement: Lymphomatous infiltration may cause cytopenias, but biopsy reveals atypical lymphoid infiltrate, not diffuse hypocellularity.

Paroxysmal Nocturnal Hemoglobinuria: May coexist with aplastic anemia. Flow cytometry identifies population of cells deficient in membrane proteins (CD55, CD59).

8. Differences with ICD-10

In the ICD-10 system, aplastic anemia was coded primarily as D61, with subdivisions to specify etiology and type. The structure included:

D61.0: Constitutional aplastic anemia
D61.1: Drug-induced aplastic anemia
D61.2: Aplastic anemia due to other external agents
D61.3: Idiopathic aplastic anemia
D61.9: Aplastic anemia, unspecified

The transition to ICD-11 with the code 3A70 represents significant changes in conceptual organization. ICD-11 adopts a more hierarchical and flexible structure, allowing additional specifications through extension codes without the need for multiple primary codes.

Main Changes:

ICD-11 uses a more consistent alphanumeric system, facilitating future expansion. The code 3A70 serves as the main category, with specific subcategories available when necessary, while maintaining simplicity in basic coding.

The definition in ICD-11 is more comprehensive and descriptive, explicitly including clinical manifestations in the official definition. This assists coders in correct code identification even without deep medical knowledge.

Practical Impact:

For healthcare systems in transition, it is essential to maintain equivalence tables between ICD-10 and ICD-11 for continuity of epidemiological data. Longitudinal studies need to consider these changes in the analysis of temporal trends.

Reimbursement and procedure authorization systems must be updated to recognize the new code. Clinical protocols and guidelines that reference ICD-10 codes require revision.

The greater descriptive precision of ICD-11 potentially reduces coding errors, but requires adequate training of professionals for complete utilization of the new functionalities.

9. Frequently Asked Questions

1. How is aplastic anemia diagnosed?

Diagnosis requires a systematic approach beginning with a complete blood count demonstrating pancytopenia. The reticulocyte count must be inadequately low. The definitive examination is bone marrow biopsy, which must show significant hypocellularity (usually <25% of expected cellularity) with replacement by adipose tissue. Bone marrow aspirate frequently results in a "dry tap" due to cellular scarcity. Complementary investigation includes exclusion of other causes: viral serologies, nutritional studies, cytogenetics, and screening for paroxysmal nocturnal hemoglobinuria. The complete diagnostic process generally requires evaluation by a specialized hematologist.

2. What is the difference between severe and non-severe aplastic anemia?

Classification is based on specific quantitative criteria. Severe aplastic anemia is defined by bone marrow cellularity below 25% associated with at least two of the following: neutrophils below 500/mm³, platelets below 20,000/mm³, or reticulocytes below 20,000/mm³. Very severe aplastic anemia presents similar criteria, but with neutrophils below 200/mm³. Non-severe forms present less pronounced cytopenias. This classification has important therapeutic implications: severe forms generally require intensive immunosuppressive therapy or bone marrow transplantation, while non-severe forms may be managed with supportive care and initial observation.

3. Is treatment available in public health systems?

Treatment of aplastic anemia is available in public health systems in many countries, although access may vary according to local resources and infrastructure. Therapeutic options include immunosuppressive therapy with antithymocyte globulin and cyclosporine, available in specialized hematology centers. Bone marrow transplantation, curative treatment for patients with a compatible donor, requires specialized transplant centers. Supportive therapy with blood transfusions and antibiotics for infections is widely available. Hematopoietic growth factors may be used in selected cases. Patients should be referred to specialized centers in hematologic diseases for evaluation and appropriate therapeutic planning.

4. How long does treatment last?

Treatment duration varies significantly according to the therapeutic modality and individual response. Initial immunosuppressive therapy generally lasts four to six months, with response assessment during this period. Cyclosporine is frequently maintained for prolonged periods (one to two years or longer) to prevent relapses. Bone marrow transplantation involves an intensive period of two to three months for the procedure and initial recovery, followed by prolonged follow-up for monitoring of complications. Supportive therapy with transfusions may be necessary for months until adequate therapeutic response. Some patients require continuous treatment or multiple therapeutic lines. Hematologic follow-up is necessary indefinitely, even after complete response, for early detection of relapses or late complications.

5. Can this code be used in medical certificates?

Yes, code 3A70 can and should be used in medical certificates when appropriate. Certificates for work leave of patients with aplastic anemia are frequently necessary, especially during acute phases, intensive treatment, or complications. The severity of the condition justifies prolonged absences. Adequate documentation should include the full diagnosis, ICD-11 code, justification for leave (risk of infections in the work environment due to neutropenia, incapacitating fatigue, need for intensive treatment), and estimated period. Patients undergoing bone marrow transplantation require prolonged leave. Certificates should be updated according to clinical evolution. It is important to emphasize that severe aplastic anemia is a potentially disabling condition, justifying social security benefits in many social security systems.

6. Is aplastic anemia curable?

The possibility of cure depends on severity, etiology, and treatment performed. Bone marrow transplantation from a compatible donor offers the possibility of cure, especially in young patients with severe aplastic anemia, with long-term survival rates exceeding 80% in specialized centers. Immunosuppressive therapy can induce complete remission in a significant percentage of patients, although the risk of relapse persists. Non-severe forms may present spontaneous recovery or stabilization with supportive treatment. Aplastic anemia secondary to reversible causes (some medications) may resolve with discontinuation of the causative agent. However, some patients develop refractory disease or progress to complications such as myelodysplastic syndrome or acute leukemia. Prolonged hematologic follow-up is essential even after therapeutic response.

7. What are the main complications of aplastic anemia?

Complications are directly related to cytopenias. Serious infections are common due to neutropenia, including bacterial sepsis, invasive fungal infections, and viral reactivation, representing an important cause of mortality. Bleeding can be severe due to thrombocytopenia, including intracranial, gastrointestinal, or pulmonary hemorrhages. Severe anemia causes debilitating fatigue, dyspnea, and may precipitate cardiovascular events in predisposed patients. Complications related to treatment include reactions to immunosuppressive therapy, graft-versus-host disease post-transplant, and opportunistic infections. Long-term complications include iron overload from repeated transfusions, clonal evolution to myelodysplastic syndrome or acute leukemia, and relapse of aplastic anemia after initial response.

8. Is there prevention for aplastic anemia?

Primary prevention is limited, but some measures reduce risks. Avoiding unnecessary exposure to medications associated with aplastic anemia (chloramphenicol, some anti-inflammatory drugs) is important. Adequate protection in occupational environments with exposure to benzene and organic solvents reduces the risk of secondary forms. Hematologic monitoring during use of potentially myelotoxic medications allows early detection. For constitutional forms, family genetic counseling is relevant. Adequate vaccination reduces the risk of associated viral infections. In already diagnosed patients, prevention of complications includes rigorous hygiene measures to reduce infections, avoiding activities with risk of trauma and bleeding, and regular hematologic follow-up for early therapeutic adjustments. Antimicrobial prophylaxis may be indicated in patients with severe neutropenia.

Conclusion

Aplastic anemia represents a serious hematologic condition that requires early recognition, adequate investigation, and precise coding. The ICD-11 code 3A70 should be applied judiciously after diagnostic confirmation through a blood count demonstrating pancytopenia and bone marrow biopsy confirming hypocellularity. Differentiation from other causes of cytopenias is essential for correct coding and appropriate management. Healthcare professionals should be familiar with diagnostic criteria, clinical manifestations, and therapeutic implications of this condition to ensure adequate documentation and optimal patient care. Precise coding contributes to epidemiologic surveillance, clinical research, and appropriate resource allocation in health systems.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Aplastic anemia

Compartir